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Abstract
Background: Hepatocellular carcinoma (HCC) staging provides a basis for calculating disease
prognosis and therapeutic guidance. Liver resection and transplantation are curative options,
and ablation therapies are applied to patients that are not candidates for curative treatment.
Survival after liver resection or ablation therapies varies.
Aims: To describe the presentation, staging, management, and outcome in patients with HCC
in our center.
Patients and methods: Forty-two patients had a 7-year prospective follow-up. Survival was
calculated with the Kaplan-Meier analysis and the log-rank test was used for its comparison
between the staging systems (Okuda, BCLC, and CLIP) and types of treatment (liver resection,
radiofrequency ablation, and no surgical treatment).
Results: The mean age of the patients was 68.9 ± 9.5 years; 57% were women. A total of 54%
of the patients presented with cirrhosis and 31% were infected with hepatitis C virus (HCV).
The mean tumor size was 6.48 ± 2.52 cm. The CLIP 0, Okuda I, and BCLC A stages had better
survival rates than the other stages (P<0.05). Survival with resection was superior (median of
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32 months and survival at 1, 3, and 5 years of 83, 39, and 19.7%, respectively) to that of both
radiofrequency ablation (median of 25 months and survival at 1 and 3 years of 90 and 17.2%,
respectively) and no surgical treatment (1 year < 5%) (P<0.05).
Conclusion: The patients at our center were diagnosed at late stages of HCC, as is the case in
other Mexican populations. Outcome in relation to CLIP and BCLC was similar to the prognoses
reported in the literature. The best results were observed in the patients with early stage
disease and those that underwent HCC resection surgery.
© 2013 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. All
rights reserved.
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Presentación, clasiﬁcación y evolución de los pacientes con carcinoma hepatocelular
en un centro de Veracruz, México
Resumen
Antecedentes: La estadiﬁcación en el carcinoma hepatocelular (CHC) otorga pronóstico y
orientación terapéutica. La resección y el trasplante hepático son opciones curativas y las
terapias de ablación se aplican a pacientes que no reciben tratamiento curativo. La sobrevida
tras la resección hepática o terapias de ablación es variada.
Objetivo: Describir la presentación, la estadiﬁcación, el manejo y la evolución de los pacientes
con CHC en nuestro centro.
Pacientes y métodos: Cuarenta y dos pacientes fueron seguidos prospectivamente durante
7 an˜os. La sobrevida se calculó mediante Kaplan-Meier y log-rank entre los sistemas de
estadiﬁcación (Okuda, BCLC y CLIP) y tipos de tratamiento (resección hepática, ablación por
radiofrecuencia y ningún tratamiento quirúrgico).
Resultados: La edad media ± desviación estándar de los pacientes fue 68,9 ± 9,5 an˜os; el 57%
fueron mujeres y el 54% cirróticos. El 31% tenía infección por VHC. El taman˜o medio del tumor
fue 6.48 ± 2.52 cm. Los estadios CLIP 0, Okuda I y BCLC A tuvieron mejor sobrevida que otros
estadios (p < 0.05). La resección tuvo mejor sobrevida (mediana: 32 meses y sobrevida a 1, 3 y
5 an˜os del 83, el 39 y 19.7%) que ablación por radiofrecuencia (25 meses, y el 90 y el 17.2% a 1
y 3 an˜os) y que ningún tratamiento quirúrgico (1 an˜o < 5%) (p < 0.05).
Conclusión: Los pacientes con CHC en nuestro centro al igual que otra población en México
son diagnosticados tardíamente. El pronóstico usando CLIP y BCLC es similar a la literatura. Los
mejores resultados se observaron en estadios tempranos y los que tuvieron resección quirúrgica
del CHC.
© 2013 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A.
Todos los derechos reservados.
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epatocellular carcinoma (HCC) is a very important health
roblem worldwide. HCC is the ﬁfth most common can-
er in the world and the most frequent primary hepatic
eoplasia.1,2 Its estimated incidence is 0.5 to one million
ew cases per year.1--4 Even though the recognized risk fac-
ors include hemochromatosis and certain environmental
oxins, hepatitis B virus (HBV) and hepatitis C virus (HCV)
re the most predominant causal factors in HCC develop-
ent worldwide. Cirrhosis of the liver is present in 50-80%
f the patients that develop HCC;5 this disease has a critical
mpact in Mexico, given that it is the third cause of death in
ur population. HCC represents > 90% of the primary hepatic
umors in Mexico, as in other countries, and the HCC mor-
ality rate in Mexico showed a 14% increase from the year
000 to 2006.6,7
a
i
c
tHCC staging systems are important for predicting patient
utcome and guiding the therapeutic approach. Conven-
ional prognostic systems for HCC such as the Okuda
lassiﬁcation have certain limitations. New systems have
urrently been proposed and validated, such as the
arcelona Clinic Liver Cancer (BCLC) system that links dis-
ase stage with treatment strategy and the Cancer of the
iver Italian Program (CLIP) that is used in patients with
dvanced disease.8
HCC outcome continues to be very poor, with a 5-year
urvival rate of < 5% when there is no type of treatment.1
p to now, resection and liver transplantation are the pri-
ary curative options for HCC. Liver transplantation offers
potential cure for HCC and also attends to the underly-
ng cirrhosis. However, less than 20% of the patients receive
urative liver resection (LR) and an even lower number of
hem receive a liver transplantation.9--11 Ablation therapy
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potential allows locoregional therapies to be carried out in
HCC patients that would otherwise not be candidates for
curative surgical treatment. Ablation therapy options
for HCC include percutaneous ethanol injection, cryother-
apy, radiofrequency ablation (RFA), and intra-arterial
chemoembolization alone or combined with RFA.9,11,12 In
some cases these locoregional therapies are used as a bridge
to liver transplantation for the patient.11 Survival after
resection or ablation therapies in HCC has a wide percentage
range due to the differences in the HCC stages analyzed in
all the studies.10,12--17 The options of systemic treatment for
unresectable HCC are limited. Recently, sorafenib has been
approved by the Food and Drug Administration for systemic
treatment of HCC.18 Likewise, few studies have analyzed
HCC presentation and its results in Mexico; the majority
have been carried out in medical centers in Mexico City at
different points in time.19--25
Aim
The aim of our study was to describe HCC presentation, stag-
ing, management, and results in patients presenting with the
disease at our center.
Methods
Forty-two patients diagnosed with HCC were evaluated for
surgical treatment at the Centro Médico Nacional «Adolfo
Ruiz Cortines» of the Instituto Mexicano del Seguro Social
in Veracruz, Mexico within the time frame of July 2005
and March 2012. The patients were followed prospectively
from their initial evaluation. The study was approved by the
local institutional ethics committee. The factors analyzed
included demographics (age, sex, and body mass index), the
presence of cirrhosis, viral hepatitis detection, and labora-
tory values. The patients were assessed using the Child-Pugh
score26 and the model for end-stage liver disease (MELD)
scoring system.27
HCC diagnosis was made during the evaluation or before
referral to our center. The laboratory values included in the
study were for coagulation (prothrombin time and interna-
tional normalized ratio), liver function tests (total bilirubin
and serum albumin), serum creatinine, viral hepatitis detec-
tion, and alpha-fetoprotein (AFP). Radiologic studies such as
computed axial tomography (CAT) and nuclear magnetic res-
onance (NMR) were carried out to determine the number of
tumors and their size. All the patients that underwent LR or
RFA had platelet counts above 100 x 103 cells/mm3. All the
patients were evaluated through chest CAT scan and bone
scintigraphy to rule out the presence of extrahepatic metas-
tases. Diagnosis was based on the established criteria 8,11 for
2 cm lesions in cirrhotic patients: arterially hypervascular-
ized lesions in 2 studies (CAT scan and NMR) or only in one
when AFP was > 400 ng/ml. Conventional histopathologic
studies with ﬁne needle aspiration biopsy were ordered in
the non-cirrhotic patients.
The patients were classiﬁed according to the Okuda sys-
tem and the BCLC and CLIP classiﬁcations. The patients
were grouped into 3 categories for this manuscript: no sur-
gical treatment (NT), LR, and RFA. All RFAs were carried
out through exploratory laparotomy or by laparoscopy when
h
t
t
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his was available to the patient (n = 2). Two cycles of RFA
ere performed when the lesions were smaller than 5 cm
nd 3 to 4 cycles when they were larger than 5 cm. Liver
unction tests were carried out and serum levels of AFP
ere determined each month in the outpatient follow-up.
iver ultrasound was ordered every 2 months and thora-
oabdominal CAT scan every 6 months or sooner when there
as recurrence suspicion. Tumor recurrence was deﬁned
y the increase in AFP and the appearance of radiologic
umors in the patients that underwent LR. Sorafenib use,
hen available to our unit, was recorded. Overall survival
as the primary aim of the study. Survival was calculated
rom the moment of evaluation up to death or loss of follow-
p. The patients were evaluated by treatment modality and
lassiﬁcation/staging system.
tatistical analysis
he data were analyzed using the SPSS 21 (SPSS, 2012,
hicago, IL, USA) software. Means ± standard deviation and
ange were used for describing the continuous variables
nd frequency and percentages for the categorical varia-
les. The variance analysis (ANOVA) was used for the
ontinuous variables with normal distribution between
he treatment groups and the chi-square test was used for
he categorical variables. Survival was calculated with the
aplan-Meier test and the log-rank (Mantel-Cox) test was
mployed to compare survival between groups. Median sur-
ival was recorded in months. Statistical signiﬁcance was set
t a p < 0.05.
esults
he mean age of all the patients was 68.9 ± 9.5 years. The
ajority of patients were women (57%) and more than half
f the patients presented with cirrhosis (54%). The most
ommon viral hepatitis in our population was HCV (31%) and
one of the patients were classiﬁed as Child-Pugh C. Patient
emographic data, the presence of cirrhosis, viral hepati-
is, and the Child-Pugh classiﬁcation for all the patients and
y treatment modality are shown in Table 1. Coincidentally,
he same number of patients received surgical treatment
either LR or RFA) as those that did not (NT) (n = 14). Both
FA and LR were performed in the same procedure in one
atient.
The liver function tests were worse in the NT patients
han in those that underwent surgical treatment (either
R or RFA). There were statistically signiﬁcant differences
n total bilirubin and serum albumin values between the
atients that underwent LR, RFA, and the NT group. Like-
ise, the NT patients had higher AFP values and MELD scores
han the patients that underwent LR or RFA, but those dif-
erences were not statistically signiﬁcant. Serum creatinine
evels were similar in all the patients. All the laboratory
alues are shown in Table 2.
The mean tumor size was 6.48 ± 2.52 cm (range: 2-13 cm)
nd the median size was 6 cm. Twenty-three patients (54.8%)
ad tumors larger than 5 cm. The NT patients had larger
umors (7.36 ± 2.37 cm, range: 5-13 cm) than the patients
hat underwent RFA (6.07 ± 2.9 cm, range: 3-13 cm) and
R (6 ± 2.48 cm, range: 2-9 cm), but with no statistical
174 G. Martinez-Mier et al.
Table 1 Clinical characteristics of the patients by groupa
LR RFA NT All
Patients (%) 14 (33.3) 14 (33.3) 14 (33.3) 42 (100)
Age (age ± SD) (range) 67.2± 9.1 (44-81) 72.3± 5.1 (64-80) 67.2 ± 12.6 (44-88) 68.9 ± 9.5 (44-88)
BMI (kg/m2 ± SD) (range) 26.8± 3.8 (18.5-33) 24.6± 3.6 (17.8-30) 25 ± 3.6 (18.5-31.4) 25.5 ± 3.7 (17.8-33.3)
Women (%) 7 (50) 10 (71.4) 7 (50) 24 (57)
Cirrhosis (%) 5 (37.5) 8 (57.1) 10 (71.4) 23 (54)
Hepatitis
No (%) 10 (71.4) 8 (57.1) 10 (71.4) 28 (66.7)
HBV (%) 0 (0) 1 (7.1) 0 (0) 1 (2.4)
HCV (%) 4 (29.6) 5 (35.7) 4 (28.6) 13 (31)
Child-Pugh
No cirrhosis (%) 9 (62.5) 6 (42.9) 4 (28.6) 19 (45)
A (%) 5 (37.5) 8 (57.1) 6 (42.9) 19 (45)
B (%) 0 (0) 0 (0) 4 (28.6) 4 (10)
RFA: radiofrequency ablation; BMI: body mass index; NT: no surgical treatment; LR: liver resection; HBV: hepatitis B virus; HCV: hepatitis
C virus.
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aa There were no statistically signiﬁcant differences between gro
igniﬁcance. Thirteen LR patients (92.9%) had a solitary
umor and only one patient (7.1%) had 3 tumors. Likewise,
n the RFA patients, 12 (85.7%) had one tumor and the rest
f the patients in that group (n=2, 14.3%) had 2 tumors.
hree NT patients (21.4%) had 3 tumors and 10 (71.4%) had
nly one tumor. The tumors were larger than 5 cm in all
he patients with more than one tumor. Fourteen patients
33.3%) had preoperative biopsy and a histopathologic diag-
osis of HCC (5 patients that underwent LR, 5 that had RFA,
nd 4 NT patients). Table 3 shows patient staging in accor-
ance with the Okuda, BCLC, and CLIP systems. The majority
f the patients were classiﬁed as Okuda stage II (57.1%).
ll the patients that underwent LR were classiﬁed as initial
CLC stage (A). The majority of the NT patients (78.6%) had
ntermediate and advanced BCLC stages (B and C). The CLIP
cores were also higher in the NT patients.
The median of survival was 16 ± 3.8 months (95% CI,
.5-23.4) in all the patients, being higher in the patients
hat underwent LR with a low CLIP score and early stages
ccording to the BCLC. Actuarial survival (Kaplan-Meier) was
arried out in the Okuda, BCLC, and CLIP systems (ﬁg. 1).
he differences in the CLIP scores were statistically more
igniﬁcant (p = 0.0001). The patients with a CLIP score
f 0 had a survival of 80.1, 50.6, and 25.1% at 1, 3, and
years, respectively. The patients with a CLIP score of 2
ad a survival at 1, 3, and 5 years of 63.2, 19.7, and 10.1%,
espectively. The patients with a CLIP score of 3 had a 1-year
urvival of 38.5% and a maximum survival of 19 months. Max-
mum survival for the patients with CLIP scores of 4 and 5
as 6.8 and 1.1 months, respectively. Only one patient with
CLIP score of 1 had a maximum survival of 6.8 months.
he patients with an early phase BCLC classiﬁcation (stage
) had the best actuarial survival rate (75.2, 30.1, and 15.3%
or 1, 3, and 5 years, respectively.) The patients in the inter-
ediate (B) and advanced (C) stages had a survival rate at
year of 30% and 37%, respectively. These differences were
tatistically signiﬁcant between stages (p = 0.01). None of
he patients classiﬁed as advanced stage (D) survived more
han 12 months. Likewise, there were no patients in stages B
d
p
r
pnd C that reached a 3-year period of survival. The patients
n Okuda stage I had a better survival at 1, 3, and 5 years
88.9, 34.2, and 11.5%) than Okuda stage II (82.6, 19.1, and
.6%). These differences were statistically signiﬁcant (p =
.023).
Survival according to treatment modality showed that
atients that underwent LR had a better survival rate than
he patients that underwent RFA or the NT patients (p =
.0001). The median survival of the patients with LR was
2 ± 12.9 months (95% CI, 6.6-57.3). The median survival
f the patients that underwent RFA was 25 ± 4.8 months
95% CI, 15.4 to 34.5) and it was 7 ± 1.6 months (95% CI, 8.5
o 23.4) for the NT patients. The actuarial survival rate at
, 3, and 5 years of the patients with LR was 83, 39.1, and
9.7%, respectively. The patients that underwent RFA had a
urvival rate at 1 year of 90% and 17.2% at 3 years. Survival
t one year in the patients that received no surgical treat-
ent (NT) was under 5%. Figure 2 shows the Kaplan-Meier
urvival curves for all the treatment modalities.
And ﬁnally, tumor recurrence in the patients with LR was
1.4% (n = 3) at 18, 40, and 50 months, all at the surgi-
al margin and in patients with anatomic resections. Two
f these patients received sorafenib and the other had no
reatment. Seven patients received sorafenib: 2 after LR,
NT patients, and 3 patients that underwent RFA.
iscussion
here were similarities in the clinical characteristics of our
atients with HCC in relation to comparisons with inter-
ational and Mexican populations. HCC usually appears in
atients above the age of 55 years, as was seen in our study,
egardless of the geographic distribution (the United States
nd Asian countries). 13,16,19,24 Since 1999, Tsukuma, et al.5emonstrated that cirrhosis was present in 50-80% of the
atients that ﬁnally developed HCC. In 1999, Fong, et al.13
eported a 70% incidence of cirrhosis of the liver in HCC
atients. The Mexican studies from that same year reported
Presentation, staging, and outcome of patients with hepatocellular carcinoma at a center in Veracruz, Mexico 175
0 12 24 36 48 60 72 84
Time (months)
0.0
0.2
0.4
0.6
0.8
1.0
Su
rv
iva
l
0.0
0.2
0.4
0.6
0.8
1.0OkudaI
II
I-Censored
II-Censored
Su
rv
iva
l
0 12 24 36 48 60 72 84
Time (months) 
Clinic
A
B
C
D
A-Censored
B-Censored
C-Censored
D-Censored
CLIP
0-Censored
1-Censored
2-Censored
3-Censored
4-Censored
5-Censored
0
1
2
3
4
5
0.0
0.2
0.4
0.6
0.8
1.0
Su
rv
iva
l
Time (months)
0 12 24 36 48 60 72 84
A B
C
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liver resection. p = 0.0001 (log-rank test).a 56% incidence of cirrhosis in the population19 and these
high ﬁgures have been maintained with percentages close
to or above 50%: thirty-eight percent in the study by Meza-
Junco et al., 22 and 72% in Mexico City federal employees.24
B
o
s
s0.0001) classiﬁcation between groups (log-rank test).
n Program.
ven though HBV is more common in the Asian countries
n which HVC has reached up to 75%,5,12 the association of
BV and HCV with HCC has also been described in the North
merican population.1,6,7 In Mexico, HCV is the second cause
f cirrhosis of the liver, which is intimately related to HCC;6,7
tudies conducted in Mexican institutions showed that HCV
as present in up to 60% of the patients with HCC.21 Simi-
ar characteristics were found in our center, given that half
f our patients had cirrhosis of the liver (54%) and HCV was
resent in almost one third of our population.
There is no current classiﬁcation system for HCC that
s accepted worldwide. The traditional classiﬁcation sys-
ems, such as Okuda or Child-Pugh, do not include different
utcome variables, such as portal hypertension grade, AFP,
umor size, and the functional status of the patient, and
o they should be employed concomitantly with other
ystems.8 The BCLC classiﬁcation and the CLIP score
nclude the Child-Pugh classiﬁcation and they are utilized
ith different outcome prediction capacities and patient
reatment.8,9 The prognostic capacity of the Okuda classiﬁ-
ation is lower than the others8 and the prognostic strength
f the CLIP score is better in the Western population.8 The
CLC classiﬁcation also serves as a guide for the treatment
f HCC in its ﬁrst stages.9 The majority of the Mexican
tudies conducted on HCC use a single staging system,
uch as the Okuda19--22 or BCLC.24 Our study demonstrated
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redictive capacity in all the systems; the advanced stages
ad a statistically signiﬁcant worse outcome than the early
nd intermediate stages. The CLIP score and the BCLC
ystem had signiﬁcantly better validity than the Okuda
ystem.
Liver transplantation offers the best survival at 5 years
n patients with HCC. However, less than 20% of the patients
eet the Milan transplantation criteria (a single HCC smaller
han 5 cm or fewer than 3 nodules smaller than 3 cm).9--11
n Mexico, results of liver transplantation for HCC are
imited28--32 and there are no Mexican studies that describe
omplete experiences with all the HCC therapies. In the
nited States, experiences from individual institutions have
een published on treatment results in patients with HCC in
hich 75% had tumors > 5 cm, with a median survival of 39
onths and an actuarial survival at 1, 3, and 5 years of 81,
4, and 37%, respectively.13 Ablation therapies (not RFA) had
median survival of 15 months.13 A sub-analysis of tumors
t the same center that were >10 cm described a median
urvival of 32 months and an actuarial survival at 5 years
f 33% with no signiﬁcant differences between the small
<10 cm) and large (> 10 cm) tumors.14 Another Western
enter10 found that only 30% of the evaluated patients with
CC were operated on (transplantation 13%, LR 12%, and
FA 5%). The best median survival corresponded to trans-
lantation patients (100.3 months), followed by LR (44.5
onths), and RFA (31.6 months) (p <0.05). Survival at one
ear for LR and RFA was 81 and 86%, respectively, survival at
years was close to 50% in both modalities (LR 57% and RFA
7%), and survival at 5 years was 47% for LR and 36% for RFA.
he relation between HCC therapies and overall survival has
ecently been analyzed from 1973 to 2003 using the SEER
atabase.17 The mean tumor size was 5 cm with a solitary
esion in 52%. LR was performed in 16% of the patients with
5-year survival rate of 35%. RFA was carried out in 25% of
he patients with a 20% survival at 5 years.17 A SEER sub-
nalysis in patients with HCC under 5 cm showed a mean
urvival of 45 months and a 39% 5-year survival rate after
R. Chinese studies have reported better mean and actu-
rial survival results with both LR16 and RFA,12 compared
ith Western studies. Our center’s study had certain sim-
larities to Western studies, such as mean tumor size, the
umber of solitary lesions, and a good actuarial 1-year sur-
ival rate with LR and RFA, but our mean survival rate was
lightly lower for LR and RFA and the 5-year survival rate was
ower when compared with the abovementioned centers. It
s worth noting that even though our median survival was
dequate, the 95% conﬁdence interval was very wide, which
ould modify our estimated actuarial 5-year survival rate.
ther factors could also have an inﬂuence on this same sur-
ival rate, such as age, patient comorbidities, and aspects
elated to LR itself, but these were not taken into con-
ideration in our statistical analysis. The comparison of all
reatment modalities was not feasible in our report because
e do not perform liver transplantation. However, it should
e mentioned that 42.8% (n = 18) of our patients would
ot be considered liver transplantation candidates accord-
ng to the BCLC9 classiﬁcation and 69% (n = 29) did not ﬁt
he Milan transplantation criteria. 9--11 Among its services,
ur hospital functions as an institutional referral center
or liver transplantation; as part of its referral criteria,
atients must be under 65 years of age, and in relation to
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Table 3 Patient staging by treatment type.
LR RFA NT All
Patients 14 (33.3%) 14 (33.3%) 14 (33.3%) 42 (100%)
Okuda
I 8 (57.1%) 10 (71.4%) 0 18 (42.9%)
II 6 (42.9%) 4 (28.6%) 14 (100%) 24 (57.1%)
BCLC
A 14 (100%) 9 (64.3%) 1 (7.1%) 24 (57.1%)
B 0 5 (35.7%) 7 (50%) 12 (28.6%)
C 0 0 4 (28.6%) 4 (9.5%)
D 0 0 2 (14.3%) 2 (4.8%)
CLIP
0 5 (35.7%) 7 (50%) 0 12 (28.6%)
1 0 1 (7.1%) 0 1 (2.4%)
2 7 (50%) 5 (35.7%) 4 (28.6%) 16 (38.1%)
3 2 (14.3%) 1 (7.1%) 8 (57.1%) 11 (26.2%)
4 0 0 1 (7.1%) 1 (2.4%)
5 0 0 1 (7.1%) 1 (2.4%)
; CLIRFA: radiofrequency ablation; BCLC: Barcelona Clinic Liver Cancer
LR: liver resection.HCC, the Milan criteria is employed, both of which would
limit the referral of our patients.
Few Mexican studies have been published that analyze
the different HCC treatment modalities (Table 4). There
w
r
p
l
Table 4 Mexican studies on HCC presentation and results.
Author (year and ref.) Age
(n)
Size (cm) Treatment
Arm (n)
Mondragón-Sánchez
et al. (1999)19
56
(63)
n/d LR: 3
NT: 34
Hernandez-Castillo
et al.a (2003)20
24
(17)
n/d LR: 4
NT: 4
Mondragón-Sánchez
et al. (2005)21
57
(43)
8
(median)
LR: 18
Ablation: 18d
Meza-Junco et al.
(2004)22
59
(135)
n/d LR: 22
Ablation: 6d
Moreno-Luna et al.b
(2005)23
23
(15)
n/d LR: 12
Mondragón-Sánchez
et al.c (2009)24
62
(30)
5.5
(mean)
RFA: 30
Ladron de Guevara
et al. (2009)25
60
(47)
8
(mean)
LR: 6
RFA: 2
NT: 23
Martínez-Mier 68
(42)
6.4
(mean)
LR: 14
RFA: 14
NT: 14
RFA: radiofrequency ablation; BCLC: Barcelona Clinic Liver Cancer; CLI
no surgical treatment; LR: liver resection; TNM: tumor node metastasi
a HCC in patients < 40 years of age.
b Fibrolamellar HCC.
c RFA, all types of tumor (HCC, n = 18).
d Ablation (not RFA).P: Cancer of the Liver Italian Program; NT: no surgical treatment;ere certain differences between those studies and our
esults: a) not taking into account the HCC studies on
atients < 40 years of age 20 and the patients with ﬁbrolamel-
ar HCC,23 the patients at our center were older than those
Stage Survival (m)
Range (CI)
Actuarial survival
(Kaplan-Meier)
I: 10%, II: 70%, III:
17%
4 (1-72)
All patients
n/d
n/d LR: 33.5
(15.2-58.7)
n/d
n/d LR: 25.3 n/d
Okuda
I: 23%, II: 55%, III:
21%
LR:37.8
(20.5-55.2)
LR 1 year: 70-80%
LR 5 years: 30-40%
TNM
I: 27%, II: 7%, III:
40%, IV: 27%
LR: 60 LR 1 year: 66%
LR 5 years: 26%
Okuda
I: 93%, II: 7%
RFA: 18
(2.6-28)
RFA 1 year: 20%
BCLC
A: 6.4%, B:
19.1%, C: 23.4%,
D: 51.1%
LR: 22.7
(21-24)
RFA: 8 (21-24)
LR 1 year: 90%,
2 years: 50%
RFA 1 year: 40%
Okuda/BCLC/CLIP
(See Table 3)
LR: 32 (6-57)
RFA: 25 (15-34)
LR: 1 year: 83%
5 years: 20%
RFA 1 year: 90%
P: Cancer of the Liver Italian Program; n/d: not determined; NT:
s.
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n the other studies, b) there was a similar number of LR and
FA procedures in our study, c) only 2 studies, besides ours,
ncluded RFA as therapy for HCC, and one of them included
ll types of hepatic tumors,24 d) our study included vari-
us staging systems for HCC, and e) the median survival of
atients that underwent RFA was higher in our study and the
urvival rate in LR was similar or superior. Despite the fact
hat these differences strengthen our study, we recognize
hat it has the following limitations, in addition to the lack
f liver transplantation results: our center does not perform
ranshepatic arterial chemoembolization,23,25 as has been
uggested for patients with BCLC stage B, which has resulted
n a more abundant performance of RFA since our initial uti-
ization of this procedure in 2005,33 thus possibly modifying
ur results; and the utilization of sorafenib in our center
s irregular, as well, which prevented us from statistically
nalyzing its use.
In conclusion, the patients with HCC in our center that
ere diagnosed in late stages of the disease have similar
haracteristics to those of other Mexican populations. Based
n the CLIP and BCLC scoring systems, the outcome for our
atients was similar to that reported in the literature. The
est results were observed in patients with early stage dis-
ase and in those that underwent surgical resection of the
CC. Opportune diagnosis of these patients is essential for
stablishing their disease management and, in turn, refer-
ing them to the specialized centers that offer the treatment
ption corresponding to their disease stage.
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